Startup profile for Seawolf Therapeutics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Seawolf Therapeutics funding, valuation and investors

Preclinical biotech developing redosable lipid-nanoparticle DNA medicines with its TRIDENT nuclear-delivery platform.

Verified company research · funding, investors and latest developments

Keep track of Seawolf Therapeutics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed plus Series A, aggregate previously raised; split amounts undisclosed

$100M combined · November 16, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$100M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · San Diego, California, USA

Investors in latest funding

Lead: Versant Ventures

Other: MPM BioImpact , Novartis Venture Fund , Eli Lilly and Company , CRISPR Therapeutics , Sixty Degree Capital , Alexandria Venture Investments , Pathway to Cures

Sources: latest funding · businesswire.com Last verified: 2026-11-17

Overview

Seawolf Therapeutics is a San Diego-based, privately held preclinical biotechnology company led by president and CEO Elizabeth Alcamo, PhD. Its TRIDENT (Targeted RNA-Induced DNA Expression via Nuclear Translocation) platform uses lipid nanoparticles to deliver 'immune-quiet' DNA encoding a therapeutic protein together with a helper factor intended to get the DNA into cell nuclei.

The goal is sustained expression and repeat dosing without the same delivery constraints as conventional viral vectors. The company reported protein expression and tolerability in nonhuman primate and mouse models; these are company-reported preclinical observations, not human clinical efficacy or safety evidence.

Its internal metabolic-disease lead is progressing toward selection of a development candidate, and no drug is approved or commercially sold. A real-world clinical pathway would require selecting a target and genetic construct, demonstrating tissue-specific biodistribution and dose-response, validating toxicity and repeat dosing, obtaining trial authorization, completing staged human trials, and obtaining marketing approval.

This is a development-stage scientific workflow, not an existing physician/patient purchase journey. The company emerged from stealth November 16, 2026 and reported $100M of cumulative capital raised across an earlier Versant-led seed and a subsequent Series A backed by Versant, MPM BioImpact, Novartis Venture Fund and other investors.

The individual amounts and actual closing dates of those two rounds are undisclosed; $100M is NOT an independently dated new Series A tranche. On the same day it disclosed a separate research and exclusive licensing collaboration with Sanofi with potential milestones of up to $1.2B and royalties for undisclosed programs, not guaranteed cash received, startup funding or acquisition consideration. Initial Sanofi payments are undisclosed.

Risks include nuclear delivery, immune reaction, off-target biodistribution, manufacture, durability, redosing, regulatory proof and clinical competition from viral vectors and RNA-LNP modalities. Source: https://www.businesswire.com/news/home/20261116723769/en/ (manager/company-issued original, available through https://www.aol.com/articles/seawolf-therapeutics-debuts-100-million-100000000.html).

Why Seawolf Therapeutics is interesting

Issuer announced $100M accumulated across Seed and Series A on November 16, 2026, not $100M independently confirmed as a Series A alone. Its separate Sanofi R&D/license deal has up to $1.2B contingent milestones; no guaranteed upfront proceeds or clinical approval disclosed.

Product & use cases

Development-stage platform, no purchasable therapy. TRIDENT encapsulates immune-quiet DNA encoding therapeutic proteins and a nuclear-access helper factor in lipid nanoparticles; company reports sustained protein expression and repeat-dosing potential in animal models. Illustrative development flow: select target/transgene -> engineer delivery formulation -> test biodistribution/dose safety in animals -> select candidate -> obtain human-trial authorization -> conduct clinical efficacy and safety trials. None of these steps establishes an approved human medicine.

  • Research-stage gene-expression therapies for rare diseases and metabolic disorders; lead program remains preclinical.
  • Sanofi partnership research on undisclosed bleeding-disorder targets; milestones contingent and initial payment undisclosed.
  • Biotech diligence comparing viral DNA vectors, transient RNA-LNP delivery and nonviral DNA delivery risks.

Key facts

  • $100M aggregate across distinct Versant-led Seed and later Series A; allocations, legal close dates and valuation undisclosed.
  • Founding investor Versant led Seed; Series A involved Versant, MPM BioImpact, Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria and Pathway to Cures.
  • Separate multi-target Sanofi agreement can pay up to $1.2B in contingent research/development/commercial milestones plus royalties; upfront not disclosed. Do not count as equity or cash realized.
  • TRIDENT LNP nuclear DNA delivery has only company-reported preclinical primate/mouse data; no approved treatment, commercial pricing or reported drug revenue.

Funding history (newest first)

Seed plus Series A, aggregate previously raised; split amounts undisclosed

2026-11-16 $100M combined
  • Versant Ventures (lead)
  • MPM BioImpact (participant)
  • Novartis Venture Fund (participant)
  • Eli Lilly and Company (participant)
  • CRISPR Therapeutics (participant)
  • Sixty Degree Capital (participant)
  • Alexandria Venture Investments (participant)
  • Pathway to Cures (participant)

Source: Read source · businesswire.com

Competitive landscape

Edge: Claimed combination of durable DNA expression with repeat dosing through a nonviral LNP; preclinical company-reported primate data only, not proven clinical superiority.

No human dosing, efficacy, revenue, validated redosing safety, patient price, manufacturing cost, or phase transition date was established from the Nov 16 issuer announcement. Clinical and immune-risk claims are vendor claims and require independent study.

  • AAV-based gene therapy alternative

    Viral DNA delivery can achieve durable expression but immunity and redosing constraints vary; human clinical evidence is more mature for some AAV products.

  • LNP-mRNA therapeutics alternative

    Clinically proven nonviral RNA delivery for certain applications, but protein expression is typically transient versus Seawolf's DNA ambition.

  • Other nonviral DNA and gene-delivery developers direct

    Research alternatives pursuing DNA nuclear delivery with distinct cargo and targeting approaches; comparable human results not established here.

Notable stories

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Seawolf Therapeutics

Practical answers founders, operators, and investors typically search for.

No individual Series A amount was disclosed. The company reported $100M in cumulative Seed and Series A funding announced together on November 16, 2026; do not assign all $100M to the Series A.
No. Up to $1.2B represents contingent future research, development and commercialization milestones plus possible royalties under a separate agreement; the upfront amount was not disclosed.
No. The company has described animal proof-of-concept, but no approved treatment or independently validated human efficacy was reported.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.